We’re so proud to partner with organizations like American Kidney Fund who are committed to increasing disease education and awareness in our communities. 🙌🏾
Check out their impact during #KidneyActionWeek .
🔗: bit.ly/3WxlF6J
•
•
•
#KidneyDisease #KidneyHealth #NOWINCLUDED

Excite and honored to be a part of AMPATH myeloma workshop in Eldoret, Kenya, to educate and mentor providers, engage with key stakeholders and advocacy groups to make bispecific antibodies available in Western Africa. #AMPATH #MoiUniversity #IUCancerCenter #IUSchoolMedicine

Sign up to join the latest event in Cure Multiple Myeloma Corporation's Ask the Doctor Breakfast Series. On 5/8 Dr. Jeffrey Zonder will be their featured speaker. These discussions are designed with patients in mind. To learn more and register:
cmmc.app.neoncrm.com/nx/portal/neon…

Hayley Thompson, Ph.D., recently spoke to Stephen Henderson, host of American Black Journal, about the challenges that still exist for minorities in Detroit and beyond regarding health equity and cancer. #YourBestChance

To watch the interview, visit mclarenhealthcare.org/3xWQlUC

Great day today at the 3rd #midwestcellular conference! I got to talk about high risk #myeloma . I’d say HRMM was my arch-nemesis if it weren’t for Stage IV AL #amyloidosis . That’s why Karmanos Cancer Institute has the AFFIRM-AL trial open. clinicaltrials.gov/study/NCT04973…

Amazing session- thank you Joseph Mikhael Drs Foti, Cortes and Ramirez

Great day for an Amyloidosis Support meeting in Kansas City at Saint Luke's Saint Luke's Mid America Heart Institute!

Thanks to our guests Anita D'Souza, Muriel Finkel, and about 70 patients and family members who took part in this meeting.

Karmanos team members convened for a research retreat to promote a research community and chart the course for our next five years of groundbreaking work in the fight against cancer.

#KarmanosCancer #CancerResearch #StrategicPlanning #Innovation #Teamwork #NCICancerCenter

Today I got the notice that NephJC.com is about to auto renew on April 26th, 2024. That date will mark #10YearsOfNephJC .

Jennifer Ahlstrom Until we have a functional cure for all or a true cure for all there will continue to be an unmet need in myeloma

ODAC unanimously votes in favor of using #MRD as an early endpoint for accelerated approval in #myeloma trials

This was a huge team effort for more than 8 years and with the generosity of unprecedented data sharing from many investigators around the world. Thank you all!
#mmsm

scroll by pic, stop, and zip back up to it thinking “ooh! human kinome tree!”. Hard to believe my imagination outnerded “sea moss”

Elated to have won the inaugural Michigan Society of Hematology and Oncology (MSHO) - Hematology Jeopardy. Alhamdulillah. Owe a lot to the training at Karmanos Hematology/Oncology Fellowship Karmanos Cancer Institute and mentors Abhinav Deol. ASH SAP/book proves to be a faithful companion.
#MSHO

And the champions are Karmanos Hematology/Oncology Fellowship Karmanos Cancer Institute

I filmed a video for PBS on screening and diagnosing multiple myeloma for primary care providers. It will air on PBS - Detroit Public Television on 4/7 at 10:30am and 4/11 at 2:30pm

Multiple Myeloma I Primary Care with Dr. Lonnie Joe - 801 youtu.be/7YDzIl3DloU?si… via YouTube

Dr. Jakub Svoboda Penn Medicine discusses armored huCART19-IL18 with encouraging early results in CD19+ lymphoma

No new safety signals w/ IL-18
CRS/ICANS rates comparable, reversible
82% ORR at 3 mo

Enrollment completed for NHL and continues for CLL, ALL
clinicaltrials.gov/study/NCT04684…

Great news for patients. Happy to see Carvitki approval jumping to 2L for the treatment of adult patients with RRMM who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. #MMSM

Our one stop website for myeloma risk:

-MM risk stratification
-SMM risk stratification
-MGUS risk stratification
-AL amyloid risk stratification

New:
-IFM Frailty score
-Waldenstrom prognosis
- iSTOP MM guide for marrow in MGUS

MyelomaRisk.com

eatoure.github.io

FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma onclive.com/view/fda-appro… via @onclive